Leukemia, Myeloid, Chronic-Phase: all 192 studies
Page 2 of 2. Open to participants first (27), then studies with results posted, then the rest; newest registration first within each.
- Stopping Tyrosine Kinase Inhibitors in Affecting Treatment-Free Remission in Patients With Chronic Phase Chronic Myeloid LeukemiaActive, not recruitingNCT03817398Phase 2
- Study in Patients With Chronic LeukemiaTerminatedNCT03807479Phase 2
- Randomized Evaluation of Radotinib Versus Imatinib in Phase III Study for Efficacy With Chinese Patients (RERISE China)Active, not recruitingNCT03722420Phase 3
- CALLS: CML and Ph+ALL Low Level Mutation Prevalence SurveyCompletedNCT03647215
- Low Dose Dasatinib (50 mg Daily) as First-line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid LeukemiaCompletedNCT03625388Phase 2
- Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase InhibitorsActive, not recruitingNCT03610971Phase 2
- Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell TransplantationWithdrawnNCT03602898Phase 2
- Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual DiseaseActive, not recruitingNCT03516279Phase 2
- Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Reducing CMV Related Complications in Patients With Blood Cancer Undergoing Donor Stem Cell TransplantWithdrawnNCT03438344Phase 2
- Imatinib Discontinuation in Patients With Chronic Myeloid Leukemia Chronic Phase With Sustained MR4logStatus unknownNCT03239886Not applicable
- Phase II Study Testing the Tolerability and the Efficacy of Bosutinib in Chronic Phase CML PatientsStatus unknownNCT03205267Phase 2
- Cessation of Tyrosine Kinase Inhibitors in Patients With Chronic-phase Chronic Myelogenous LeukaemiaStatus unknownNCT03131986
- Dasatinib Versus Nilotinib for Treatment Naïve Chronic Myeloid LeukemiaTerminatedNCT03079505Phase 3
- Determining Change in Cardiovascular and Metabolic Risks in Patients With Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United StatesCompletedNCT03045120
- A Study of Ruxolitinib in Combination With Nilotinib in Patients With Chronic Phase CMLWithdrawnNCT02973711Phase 1/2
- Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic MalignanciesCompletedNCT02960646Phase 1
- Study to Assess Efficacy and Safety of Inecalcitol in Imatinib-Treated Residual Chronic Myeloid Leukaemia: INIM StudyStatus unknownNCT02949570Phase 2
- Pioglityazone and Imatinib for CML PatientsCompletedNCT02888964Phase 2
- Therapies in Combination or Sequentially With Tyrosine Kinase Inhibitors (TKIs) in Chronic Phase Chronic Myelogenous Leukemia Patients in CCR (ACTIW)Active, not recruitingNCT02767063Phase 1/2
- Sirolimus and Mycophenolate Mofetil in Preventing GVHD in Patients With Hematologic Malignancies Undergoing HSCTTerminatedNCT02728700Phase 1
- Dasatinib and Venetoclax in Treating Patients With Philadelphia Chromosome Positive or BCR-ABL1 Positive Early Chronic Phase Chronic Myelogenous LeukemiaActive, not recruitingNCT02689440Phase 2
- Treating Patients With Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) With DasatinibCompletedNCT02348957
- Addition of P1101 to Imatinib Treatment in Patients With Chronic Phase Chronic Myeloid Leukaemia Not Achieving a Complete Molecular ResponseCompletedNCT01933906Phase 1
- Phase I/II Study of Nilotinib/Ruxolitinb Therapy for TKI Resistant Ph-LeukemiaCompletedNCT01914484Phase 1/2
- Dasatinib for Patients Achieving Complete Molecular Response for Cure D-NewS TrialStatus unknownNCT01887561Phase 2
- Nilotinib 300 mg BID in Newly Diagnosed CP-CML Patients to Verify Disappearance of CD34+/Lin-Ph+ CellsCompletedNCT01856283Phase 2
- Chronic Myelod Leukemia Registry at Asan Medical CenterTerminatedNCT01761695
- Safety and Efficacy of Pegylated IFN-alpha 2B Added to Dasatinib in Newly Diagnosed Chronic Phase Myeloid LeukemiaCompletedNCT01725204Phase 2
- Ruxolitinib in Combination With Nilotinib in Chronic Myeloid Leukemia (CML) PatientsCompletedNCT01702064Phase 1
- Imatinib Response in Patients With Chronic Myeloid Leukemia (CML) in Function of Abl PolymorphismsWithdrawnNCT01650467
- NK Cells in Cord Blood TransplantationStatus unknownNCT01619761Phase 1
- Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell TransplantCompletedNCT01588015Phase 1
- Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell TransplantWithdrawnNCT01558778Not applicable
- Pilot Study to Assess Telemonitoring of Gleevec (Imatinib Mesylate) or Tasigna (Niltinib) TherapyTerminatedNCT01490775Not applicable
- Sirolimus/Tacrolimus Combination After HLA Matched Related Peripheral Blood Stem Cell TransplantsTerminatedNCT01488253Phase 2
- Dasatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia in JapanStatus unknownNCT01464411
- Comparison of Imatinib Versus Dasatinib in Patients With Newly-diagnosed Chronic Phase Chronic Myeloid LeukaemiaCompletedNCT01460693Phase 3
- Dasatinib and Cyclosporine in Treating Patients With Chronic Myelogenous Leukemia Refractory or Intolerant to Imatinib MesylateTerminatedNCT01426334Phase 1
- Nilotinib + Pegylated Interferon Alpha 2a for Untreated Chronic Phase Chronic Myelogenous LeukemiaCompletedNCT01294618Phase 2
- MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or LeukemiaCompletedNCT01231919Phase 1
- Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell TransplantActive, not recruitingNCT01199562
- RAD001 in Patients With Chronic Phase Chronic Myeloid Leukemia w/ Molecular Disease.WithdrawnNCT01188889Phase 1/2
- Treatment With Second Generation Tyrosine Kinase Inhibitors (2G TKI) Post Imatinib Failure SurveyCompletedNCT01188278
- High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin LymphomaCompletedNCT01177371Phase 2
- Infusion of Off-the-Shelf Expanded Cord Blood Cells to Augment Cord Blood Transplant in Patients With Hematologic MalignanciesCompletedNCT01175785Phase 2
- Late Chronic Phase Chronic Myelogenous LeukemiaCompletedNCT01092741Phase 2
- Discontinuation of Imatinib Mesylate in Patients With Chronic-Phase Chronic Myeloid Leukemia Previously Treated With Interferon-AlphaTerminatedNCT01073436
- Fludarabine Phosphate, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Peripheral Blood Stem Cell Transplant, Tacrolimus, and Methotrexate in Treating Patients With Myeloid MalignanciesCompletedNCT01056614Phase 2
- Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for CancerCompletedNCT01053494Not applicable
- 3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With CancerActive, not recruitingNCT00935090
- Studying Fentanyl in Patients With CancerTerminatedNCT00899951
- Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral TherapyCompletedNCT00890747Phase 1
- Nilotinib in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous LeukemiaCompletedNCT00809211Phase 2
- Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late ComplicationsCompletedNCT00799461Phase 3
- Nilotinib and Imatinib Mesylate in Treating Patients With Early Chronic Phase Chronic Myelogenous LeukemiaCompletedNCT00769327Phase 2
- Panobinostat (LBH589) and Imatinib Mesylate in Treating Patients With Previously Treated Chronic Phase Chronic Myelogenous LeukemiaCompletedNCT00686218Phase 1
- Exploratory Study of IMATINIB High Dose in Intermediate Risk Chronic Myeloid Leukemia in Chronic PhaseCompletedNCT00510926Phase 2
- Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic CancerCompletedNCT00489203Phase 2
- Glivec® (Imatinib Mesylate, STI571) in Monotherapy Versus Glivec®-Interferon Alpha in the Treatment of Chronic-Phase Chronic Myeloid LeukaemiaCompletedNCT00390897Phase 4
- A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Blood Unit in Patients Undergoing Cord Blood Transplant for Hematologic MalignanciesCompletedNCT00343798Phase 1
- Phase I Study of Dasatinib (BMS-354825) and Imatinib in Subjects With Chronic Myeloid Leukemia in Chronic PhaseWithdrawnNCT00324077Phase 1
- Total-Body Irradiation and Cyclophosphamide in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer and Other DiseasesCompletedNCT00317785Phase 2
- Low-Dose Fludarabine, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic CancerCompletedNCT00301951Phase 1
- Vaccine Therapy and Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous LeukemiaCompletedNCT00301093Phase 1
- AFR10 - Combination Therapy of Imatinib Mesylate (IM) + Alpha-2A Interferon for Chronic Phase CML Patients Resistant or Refractory to IM Used as Single Therapy for at Least One YearStatus unknownNCT00146913Phase 2
- BMS-354825 or Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Did Not Respond to Previous Imatinib MesylateStatus unknownNCT00112775Phase 2
- BMS-354825 in Patients With Chronic Accelerated, or Blast Phase Chronic Myelogenous Leukemia or Philadelphia Positive Acute Lymphoblastic LeukemiaCompletedNCT00103701Phase 1
- Temsirolimus and Imatinib Mesylate in Treating Patients With Chronic Myelogenous LeukemiaTerminatedNCT00101088Phase 1
- 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Did Not Respond to Imatinib MesylateCompletedNCT00100997Phase 1
- Everolimus and Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia Who Are Not in Complete Cytogenetic Remission After Previous Imatinib MesylateCompletedNCT00093639Phase 1/2
- Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell TransplantCompletedNCT00078858Phase 1/2
- Sargramostim in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia Who Are Not in Complete Cytogenetic Remission Following Initial TreatmentCompletedNCT00072579Phase 2
- BMS-354825 in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Is Resistant to Imatinib MesylateCompletedNCT00064233Phase 1
- Imatinib Mesylate With or Without Interferon Alfa or Cytarabine Compared With Interferon Alfa Followed by Donor Stem Cell Transplant in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous LeukemiaCompletedNCT00055874Phase 3
- Oblimersen and Imatinib Mesylate in Treating Patients With Chronic Myelogenous LeukemiaCompletedNCT00049192Phase 2
- Therapy of Early Chronic Phase CML With GleevecCompletedNCT00048672Phase 2
- Interferon Alfa and Imatinib Mesylate in Treating Patients With Chronic Myelogenous LeukemiaCompletedNCT00045422Phase 2
- Total-Body Irradiation, Fludarabine, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic CancerCompletedNCT00044954Phase 2
- Zarnestra and Gleevec in Chronic Phase Chronic Myelogenous LeukemiaCompletedNCT00040105Phase 1
- Imatinib Mesylate in Treating Patients With Chronic Myelogenous LeukemiaCompletedNCT00030394Phase 2
- Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver DysfunctionCompletedNCT00025415Phase 1
- Chemotherapy Plus Sargramostim in Treating Patients With Refractory Myeloid CancerCompletedNCT00012376Phase 1
- Homoharringtonine in Treating Patients With Chronic Phase Chronic Myelogenous LeukemiaCompletedNCT00006364Phase 2
- Arsenic Trioxide in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Has Not Responded to Previous TreatmentWithdrawnNCT00006091Phase 2
- Fludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney CancerCompletedNCT00005799Not applicable
- Vaccine Therapy Plus Immune Adjuvant in Treating Patients With Chronic Myeloid Leukemia, Acute Myeloid Leukemia, or Myelodysplastic SyndromeCompletedNCT00004918Phase 1/2
- Bone Marrow Transplantation in Treating Patients With Multiple Myeloma, Chronic Phase Chronic Myelogenous Leukemia, or Agnogenic Myeloid MetaplasiaCompletedNCT00004181Phase 2
- Homoharringtonine Plus Low-Dose Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia in Chronic PhaseCompletedNCT00003694Phase 2
- Interferon Alfa Plus Sargramostim in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous LeukemiaTerminatedNCT00003561Phase 2
- Interleukin-12 Followed by Interferon Alfa in Treating Patients With Advanced CancerCompletedNCT00003451Phase 1
- Chemotherapy and Biological Therapy in Treating Patients With Chronic Phase Chronic Myelogenous LeukemiaCompletedNCT00003239Phase 2
- Peripheral Stem Cell Transplantation Plus Filgrastim in Treating Patients With Acute or Chronic Myelogenous LeukemiaCompletedNCT00002833Phase 2